Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Allen

Showing results (191-200 of 202) with videos related to

Pageof 21
Sort By:
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Open Forum Infectious Diseases|March 13, 2026
Characteristics of Young Children Hospitalized With Acute Respiratory Failure From Infection With Respiratory Syncytial Virus, SARS-CoV-2, or Both, November 2023-March 2024Regina M Simeone, Margaret M Newhams, Laura D Zambrano, et al.
Epidemiology (Cambridge, Mass.)|May 18, 2022
Understanding Variation in Rotavirus Vaccine Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic MisclassificationAvnika B Amin, Timothy L Lash, Jacqueline E Tate, et al.
Pediatrics|September 10, 2024
Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022Alpha Oumar Diallo, Mary E Wikswo, Iddrisu Sulemana, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
MMWR. Morbidity and Mortality Weekly Report|December 5, 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025Laura D Zambrano, Regina M Simeone, Margaret M Newhams, et al.
The Journal of Infectious Diseases|June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, One Dintwe, Sheetal Sawant, et al.
JAMA Network Open|August 15, 2023
Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal PeakNatasha Halasa, Laura D Zambrano, Justin Z Amarin, et al.
The Journal of Infectious Diseases|January 15, 2025
Assessing Clinical Improvement of Infants Hospitalized for Respiratory Syncytial Virus-Related Critical IllnessShannon B Leland, Laura D Zambrano, Steven J Staffa, et al.
Pageof 21

Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Open Forum Infectious Diseases|March 13, 2026
Characteristics of Young Children Hospitalized With Acute Respiratory Failure From Infection With Respiratory Syncytial Virus, SARS-CoV-2, or Both, November 2023-March 2024Regina M Simeone, Margaret M Newhams, Laura D Zambrano, et al.
Epidemiology (Cambridge, Mass.)|May 18, 2022
Understanding Variation in Rotavirus Vaccine Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic MisclassificationAvnika B Amin, Timothy L Lash, Jacqueline E Tate, et al.
Pediatrics|September 10, 2024
Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022Alpha Oumar Diallo, Mary E Wikswo, Iddrisu Sulemana, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
MMWR. Morbidity and Mortality Weekly Report|December 5, 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025Laura D Zambrano, Regina M Simeone, Margaret M Newhams, et al.
The Journal of Infectious Diseases|June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, One Dintwe, Sheetal Sawant, et al.
JAMA Network Open|August 15, 2023
Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal PeakNatasha Halasa, Laura D Zambrano, Justin Z Amarin, et al.
The Journal of Infectious Diseases|January 15, 2025
Assessing Clinical Improvement of Infants Hospitalized for Respiratory Syncytial Virus-Related Critical IllnessShannon B Leland, Laura D Zambrano, Steven J Staffa, et al.
Pageof 21